title: [Efficacy of the combination drug vasobral in chronic vascular encephalopathy].
abstract: OBJECTIVE
  Despite the high prevalence of chronic vascular encephalopathy, its diagnosis and treatment remain understudied. This observational multicenter trial assessed the efficacy and safety of vasobral in patients with cerebral ischemia.
  
  
  METHODS
  The open observational study was carried out in 37 centers in 11 Russian cities and included 300 patients with confirmed diagnosis of chronic vascular encephalopathy, stages 1 and 2, without dementia. The patients received 1 tablet (4 mg α-dihydroergocryptine and 40 mg caffeine) 2 times a day during 3 months.
  
  
  CONCLUSIONS
  There was an improvement of cognitive and affective status as well as quality of life and a decrease of subjective signs of chronic vascular encephalopathy. Vasobral did not cause significant fluctuations of arterial pressure and was safe for patients with chronic vascular encephalopathy and arterial hypertension.
authors.forename: O S
authors.initials: OS
authors.lastname: Levin
authors.forename: E R
authors.initials: ER
authors.lastname: Barantsevich
authors.forename: G N
authors.initials: GN
authors.lastname: Belskaya
authors.forename: E E
authors.initials: EE
authors.lastname: Vasenina
authors.forename: S V
authors.initials: SV
authors.lastname: Kopishinskaya
authors.forename: I G
authors.initials: IG
authors.lastname: Lukashevich
authors.forename: O D
authors.initials: OD
authors.lastname: Ostroumova
authors.forename: O V
authors.initials: OV
authors.lastname: Psokhina
authors.forename: M A
authors.initials: MA
authors.lastname: Radiuk
mesh_terms: D000328:Adult; D000368:Aged; D001925:Brain Damage, Chronic / Q000188:drug therapy*; D002545:Brain Ischemia / Q000188:drug therapy*; D002110:Caffeine / Q000009:adverse effects / Q000627:therapeutic use*; D059345:Cerebral Small Vessel Diseases / Q000188:drug therapy*; D004088:Dihydroergotoxine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D004088:Dihydroergotoxine; D002110:Caffeine; C055581:Vasobral